Harpoon Therapeutics Announces Updated Interim Tolerability
Confirmed response rate 35% (11/31), across all tumor types and patient cohorts treated with 1 mg priming dose, including three confirmed, complete...
Source: globenewswire.com
Page 2 - Activating Construct News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Activating Construct. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Activating Construct Today - Breaking & Trending Today
Harpoon Therapeutics to Present Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023
SOUTH SAN FRANCISCO, Calif., Oct. 09, 2023 -- Harpoon Therapeutics, Inc. , a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it will present interim...
Source: marketscreener.com
Harpoon Therapeutics Presents HPN217 Interim Phase 1 Data at the IMS Annual Meeting
Target dose of 12 mg demonstrates robust early activity and manageable tolerability profile:– 63% ORR, 16% cytokine release syndrome , No ICANS – Phase 1 data set, including recommended Phase 2...
Source: marketscreener.com
HARPOON THERAPEUTICS ANNOUNCES FIRST PATIENTS WITH SMALL CELL LUNG CANCER DOSED IN HPN328 COMBINATION COHORT
SOUTH SAN FRANCISCO - Harpoon Therapeutics, Inc. , a clinical-stage immuno-oncology company developing novel T cell engagers, today announced dosing of the first patients with small cell lung cancer ...
Source: marketscreener.com
AbbVie ditches license option for Harpoon's TriTAC multiple myeloma program
Going forward, Harpoon said the TriTAC multiple myeloma program will remain exclusively within the company as it plans to complete an ongoing Phase 1 clinical trial with data to support the next phase of development.
Source: mmm-online.com